The Canada Lateral Flow Assays Market was valued at $364.4 Million in 2025 and projected to reach to $502.1 Million by 2030, representing a compound annual growth rate of 6.6%. Canada's lateral flow assays market is positioned for steady growth through 2030, supported by the country's advanced healthcare infrastructure and emphasis on accessible diagnostic solutions.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Canada's lateral flow assays market is valued at $364.4 million in 2025 and is projected to reach $502.1 million by 2030, demonstrating consistent market expansion.
The Canadian market is growing at a CAGR of 6.6% from 2025 to 2030, reflecting steady demand for rapid diagnostic solutions in clinical and point-of-care settings.
Canada's robust healthcare system and universal coverage model drive adoption of lateral flow assays across hospitals, clinics, and community health centers nationwide.
Increasing preference for rapid, cost-effective diagnostic testing in Canada's healthcare facilities is accelerating the uptake of lateral flow assay technologies.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
The BinaxNOW and Panbio lateral flow assay platforms are used in hospitals, pharmacies, airports, and community testing centers for the rapid detection of infectious diseases such as influenza, malaria, HIV, and RSV. | These assays deliver accurate results within 15–20 minutes, enabling fast clinical decisions and reducing dependency on centralized laboratories. Their scalability supports mass-screening programs, and digital connectivity features allow seamless reporting and public health surveillance. |
|
|
Roche’s rapid antigen and multimarker LFA tests, including Influenza A/B tests, are used in hospitals, urgent care centers, and corporate or community screening setups for rapid infectious disease identification. | These products offer high diagnostic accuracy validated across global healthcare networks, helping clinicians reduce misdiagnosis and streamline infection-control protocols. Their rapid turnaround enhances outbreak response and minimizes patient waiting times. |
|
|
Cepheid collaborates on LFA-compatible workflows for decentralized infectious disease and respiratory testing in settings where molecular platforms are not feasible. | These solutions support hybrid testing pathways where LFAs provide quick initial screening followed by confirmatory molecular tests, improving diagnostic efficiency in low-resource or high-volume environments. |
|
|
The BD Veritor Plus System is used in hospitals, clinics, pharmacies, schools, and occupational health centers for rapid antigen testing, including influenza A/B, RSV, and Group A Strep. | The system’s analyzer-based interpretation improves accuracy, minimizes user error, and provides connectivity for electronic medical record (EMR) integration and large-scale surveillance. |
|
|
The Sofia Flu A+B and Strep A lateral flow assays are used across hospitals, urgent care centers, and physician offices with the Sofia Analyzer for rapid respiratory and infectious disease diagnostics. | Their fluorescent immunoassay technology provides higher sensitivity than traditional LFAs, while the analyzer automates result interpretation and supports rapid “test-and-treat” decision-making. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | SEXUALLY TRANSMITTED INFECTION TESTING (Disease Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 8% from 2025 to 2030 |
| Largest Segment | KITS & REAGENTS (Product) |
| Market Size Base Year (Billions) | ~USD 8.52 (2025) |
| Revenue Forecast (Billions) | ~USD 12.52 (2030) |
| Segments Covered | Product, Application, Type, Disease Type, Technique |
5 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| DIAGNOSTIC LABORATORIES | 77.4 | 82.3 | 87.5 | 93.4 | 99.8 | 107 | 115 | 123.7 | 7.2 |
| HOME CARE SETTINGS | 86.7 | 92.6 | 99 | 106.1 | 114.1 | 122.9 | 132.6 | 143.4 | 7.7 |
| HOSPITALS & CLINICS | 148.9 | 156.3 | 164.2 | 173 | 182.7 | 193.4 | 205 | 217.7 | 5.8 |
| OTHER END USERS | 7.6 | 7.9 | 8.3 | 8.7 | 9.1 | 9.6 | 10.1 | 10.7 | 5.2 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 5 | 5.2 | 5.4 | 5.6 | 5.8 | 6.1 | 6.4 | 6.8 | 4.7 |
| TOTAL | 325.6 | 344.3 | 364.4 | 386.8 | 411.5 | 439 | 469.1 | 502.1 | 6.6 |
Canada's lateral flow assays market is valued at $364.4 million in 2025 and is expected to grow to $502.1 million by 2030.
Canada's lateral flow assays market is projected to grow at a compound annual growth rate (CAGR) of 6.6% from 2025 to 2030.
In Canada, lateral flow assays are primarily used for infectious disease testing, pregnancy diagnostics, and chronic disease management in clinical and point-of-care settings.
Canada's robust healthcare infrastructure, strong regulatory frameworks, and high healthcare spending facilitate widespread adoption of lateral flow assays across hospitals and community-based diagnostic centers.
Canada's market growth will be driven by technological innovations, expanded product portfolios, growing consumer awareness of rapid testing, and the nation's emphasis on preventive healthcare and early disease detection.
The study involved major activities in estimating the current market size for the global lateral flow assays market.
Exhaustive secondary research was done to collect information on the lateral flow assays industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the lateral flow assays market.
The four steps involved in estimating the market size are:
The secondary research process involves the widespread use of secondary sources, directories, databases, white papers, annual reports, investor presentations, SEC filings of companies and publications from government sources [such as US Food and Drug Administration, World Health Organization (WHO), Centers for Disease Control and Prevention, International Organization for Standardization (ISO), Agency for Healthcare Research and Quality, were referred to identify and collect information for the global lateral flow assays market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends, to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the lateral flow assays market. The primary sources from the demand side include hospitals, clinics, diagnostic laboratories, pharmaceutical and biotechnology companies. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.
The following is a breakdown of the primary respondents:
Note 1: Other designations include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global lateral flow assays market. All the major service providers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was done for the major players. The global lateral flow assays market was split into various segments and sub-segments based on:
The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.
The research methodology used to estimate the market size includes the following:

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Lateral flow assays, or lateral flow immunochromatographic assays, are simple-to-use diagnostic devices to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals, or contaminants in water supplies, without requiring specialized equipment.
Full forecast, segment splits, and company analysis for all Lateral Flow Assays Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report